GCAC is proud to announce the release of the White Paper on ‘A Global Community for Medicinal Cannabis Users, Researchers and Practitioners’. The purpose of this White Paper is to define the path required to create a global dataset that identifies the best medical cannabis products by efficacy for a particular ailment.
The Medical Cannabis Paradox
Cannabis has been well known for centuries for its medical benefits, including pain management, seizure remediation, managing muscle spasms and a range of others. However, over the past century, cannabis has been a proscribed substance and treated as a law-enforcement challenge.
As a result, there is a lack of well-researched medical data as well as an absence of anecdotal user information. As little as 6% of cannabis research has focused on the benefits, and it has historically been very difficult to get approval for properly controlled cannabis studies.
Doctors and other practitioners don’t have trusted information on which to base clinical decisions, and regulators lack long-term information. All of these factors have led to significant under-prescription of medical cannabis and a large, unfilled demand for quality research, new product delivery and consumer information on its uses and effects.